Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cellectis S.A. (CLLS : NSDQ)

• Company Description    Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. Number of Employees: 229

• Price / Volume Information    Yesterday's Closing Price: $3.50 Daily Weekly Monthly 20 Day Moving Average: 23,215 shares Shares Outstanding: 100.34 (millions) Market Capitalization: $351.19 (millions) Beta: 2.94 52 Week High: $5.48 52 Week Low: $1.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.49% -14.86% 12 Week -12.94% -19.51% Year To Date -27.69% -33.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8 RUE DE LA CROIX JARRY - PARIS LLE-DE-FRANCE,I0 75013 FRA ph: 33-1-81-69-16-00 fax: 33-1-81-69-16-06 investors@cellectis.com http://www.cellectis.com

• General Corporate Information    Officers Andre Choulika - Chief Executive Officer and Co-Founder Jean-Pierre Garnier - Chairman of the Board and Director Arthur Stril - Chief Financial Officer & Chief Business Officer Laurent Arthaud - Director Donald A. Bergstrom - Director Peer Information Cellectis S.A. (CORR.) Cellectis S.A. (RSPI) Cellectis S.A. (CGXP) Cellectis S.A. (BGEN) Cellectis S.A. (GTBP) Cellectis S.A. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117K103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/03/26 Share - Related Items Shares Outstanding: 100.34 Most Recent Split Date: (:1) Beta: 2.94 Market Capitalization: $351.19 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.86 Price/Cash Flow: - Price / Sales: 4.68 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 30.77% Sales Growth vs. Year Ago Period: -37.25% vs. Previous Quarter: -38.16% ROE 03/31/26 - -80.66 12/31/25 - -69.38 09/30/25 - -51.22 ROA 03/31/26 - -20.51 12/31/25 - -19.51 09/30/25 - -15.77 Current Ratio 03/31/26 - 1.52 12/31/25 - 1.62 09/30/25 - 1.49 Quick Ratio 03/31/26 - 1.52 12/31/25 - 1.62 09/30/25 - 1.49 Operating Margin 03/31/26 - -89.51 12/31/25 - -84.92 09/30/25 - -56.62 Net Margin 03/31/26 - -89.51 12/31/25 - -84.92 09/30/25 - -58.06 Pre-Tax Margin 03/31/26 - -90.01 12/31/25 - -85.46 09/30/25 - -34.63 Book Value 03/31/26 - 0.60 12/31/25 - 0.76 09/30/25 - 1.81 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 1.13 12/31/25 - 0.98 09/30/25 - 0.63 Debt-to-Capital 03/31/26 - 52.97 12/31/25 - 49.37 09/30/25 - 38.69

Powered by Zacks Investment Research ©